Crossmark

Therapeutic impact of vildagliptin vs. gliclazide on insulin resistance and advanced glycated end product levels in newly diagnosed Egyptian diabetics: a randomized controlled trial

Crossref DOI link: https://doi.org/10.1007/s00228-025-03894-8

Published Online: 2025-08-05

Published Print: 2025-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Elemary, Toka

Abdelrahim, Mohamed E. A.

Nicola, Mina

Zaafar, Dalia
Funding

Funding for this research was provided by:

Modern Academy for Technology, Computer Science & Management
License Information

Text and Data Mining valid from 2025-08-05

Version of Record valid from 2025-08-05
More Information

Article History

Received: 8 May 2025

Accepted: 21 July 2025

First Online: 5 August 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below